LISA-TRACKER Secukinumab
Product Description
LISA-TRACKER Secukinumab is an enzyme linked immunoassay (ELISA) for the quantitative determination of Secukinumab (anti-Interleukin 17-A antibody) in human serum.
- Comprehensive menu in inflammatory diseases and oncology
- Validated on principle drug and biosimilars
- Ready to use reagents
- Standardised protocols from sample collection to result interpretation
- Automation ready – protocols available on several open platform ELISA systems
-
- Baeten D et al. Secukinumab, interleukin-17A inhibition in ankylosing spondylitis. N Engl J Med, 2015; 373: 2534-48.
- Baraliakos X et al. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the phase 3 MEASURE 1 trial. Clinical and Experimental Rheumatology, 2017.
- Blauvelt A et al. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than Ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study. JEADV, 2017, 31, 1693-1699.
- Bruin G et al. Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis. The Journal of Clinical Pharmacology, 2017, 57(7), 876-885.
- Koenders MI et al. Secukinumab for rheumatology: development and its potential place in therapy. Drug Design, Development and Therapy, 2016:10, 2069-2080.
- Pavelka K et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-bind phase 3 study, MEASURE 3. Arthritis Research & Therapy, 2017, 19:285.
- Product Code: LTS-002-48
- Number of Tests: 48
- Sample Type: Serum or plasma
- Sample Volume: 100 μL (following predilution)
- Assay Range: 4 – 120 μg/mL
- Add to Enquiry Basket
Interested? Enquire now.
Add to Enquiry Basket
Related Products
| Assays | Certification | Platform | Clinical Area | Portfolio | RUO/IVD |
|---|---|---|---|---|---|
| LISA-TRACKER anti-Secukinumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Secukinumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Adalimumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Infliximab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Certolizumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Etanercept | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Golimumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Rituximab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Tocilizumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Ustekinumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Vedolizumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD |